This unimolecular dual incretin, which was derived from a mixed sequence of GLP- 1 and GIP, showed improved antihyperglycemic and insulinotropic activity compared to selective GLP- 1 agonists
Phase 3 results are expected throughout the remainder of the TRIUMPH program, with potential FDA approval estimated for 2027 at the earliest
[DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted] 47.Wei X., Jia R., Wang G., Hong S., Song L., Sun B., Chen K., Wang N., Wang Q., Luo X., et al
Interestingly, research suggests that GLP-1 may be impaired in some people with obesity, even if they have a normal glucose tolerance
Retatrutide is produced using solid-phase peptide synthesis (SPPS), a method that allows researchers to assemble the peptide sequence step-by-step using protected amino acids, ensuring precise control over the final structure
(1) Prevention from DPP-4 degradation